文献速递造血干细胞移植与细胞治疗

表达MHC特异性CAR的人CD8+ Treg增强对NSG小鼠皮肤排斥和GVHD的抑制

Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice.
PubMed 文献 · Blood Adv · 2019-01-01

该研究将源自HLA-A*02特异性抗体的CAR(A2-CAR)稳定导入人CD8+ Treg,并建立临床兼容的转导扩增方案。A2-CAR CD8+ Treg表型未变、被特异性激活且对HLA-A*02+肾内皮细胞无细胞毒活性;在体外及NSG小鼠人皮肤移植排斥和GVHD模型中,其抑制HLA-A*02错配免疫反应的能力强于对照CAR CD8+ Treg。

要点

  • A2-CAR CD8+ Treg表型未变,被特异性激活,对HLA-A*02+肾内皮细胞无细胞毒活性。
  • 在体外及NSG小鼠皮肤移植排斥和GVHD模型中,A2-CAR CD8+ Treg抑制HLA-A*02错配免疫反应强于对照CAR。
  • 给药后至少100天,A2-CAR CD8+ Treg组人皮肤移植物完整性得以保持。

核心结论

  • CAR工程化可开发抗原特异性CD8+ Treg,有望用于移植及潜在其他疾病的临床试验。

研究设计与样本

  • 研究将源自HLA-A*02特异性抗体的A2-CAR稳定导入人CD8+ Treg,并建立临床兼容的转导扩增方案。
  • 在体外及NSG小鼠人皮肤移植排斥和GVHD模型中评价A2-CAR CD8+ Treg的功能。

主要发现

  • A2-CAR CD8+ Treg表型未因转导扩增过程改变,被特异性激活,且对HLA-A*02+肾内皮细胞无细胞毒活性。
  • 体外和体内实验中,A2-CAR CD8+ Treg抑制HLA-A*02错配诱导的免疫反应强于对照CAR CD8+ Treg。
  • 给药后至少100天,A2-CAR CD8+ Treg组人皮肤移植物完整性保持。
  • A2-CAR CD8+ Treg与HLA-A*02+肾内皮细胞相互作用导致内皮细胞精细调节和促耐受激活,而无细胞毒作用。

临床怎么用

  • 该CAR-CD8+ Treg策略支持在移植领域开展抗原特异性Treg临床试验,并可能拓展至其他疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polyclonal CD8+CD45RClow/- Tregs are potent regulatory cells able to control solid organ transplantation rejection and even induce tolerance. However, donor major histocompatibility complex (MHC)-specific Tregs are more potent than polyclonal Tregs in suppressing T-cell responses and preventing acute as well as chronic rejection in rodent models. The difficulty of identifying disease-relevant antigens able to stimulate Tregs has reduced the possibility of obtaining antigen-specific Tregs. To bypass this requirement and gain the advantage of antigen specificity, and thus improve the therapeutic potential of CD8+ Tregs, we stably introduced a chimeric antigen receptor (CAR) derived from a HLA-A*02 antigen-specific antibody (A2-CAR) in human CD8+ Tregs and developed a clinically compatible protocol of transduction and expansion. We demonstrated that A2-CAR CD8+ Tregs were not phenotypically altered by the process, were specifically activated, and did not exhibit cytotoxic activity toward HLA-A*02+ kidney endothelial cells (ECs). We showed that A2-CAR CD8+ Tregs were more potent suppressors of immune responses induced by HLA-A*02 mismatch than control-CAR CD8+ Tregs, both in vitro and in vivo, in models of human skin graft rejection and graft-versus-host disease (GVHD) in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice. We showed that integrity of human skin graft was preserved with A2-CAR CD8+ Tregs at least 100 days in vivo after administration, and that interaction between the A2-CAR CD8+ Tregs and HLA-A*02+ kidney ECs resulted in a fine-tuned and protolerogenic activation of the ECs without cytotoxicity. Together, our results demonstrated the relevance of the CAR engineering approach to develop antigen-specific CAR-CD8+ Tregs for clinical trials in transplantation, and potentially in other diseases.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bézie S, Charreau B, Vimond N, et al. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice. Blood Adv. 2019. PMID: 31730699. doi:10.1182/bloodadvances.2019000411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。